Institute of Experimental Medicine CAS

An invention developed by scientists from the IEM CAS and the IOCB CAS has been granted its fourth international patent

Published 23. 03. 2022

In addition to Japan, Australia and Europe, the new invention "synthesis and the use of polysubstituted pyrimidines" is now also protected in the United States.

Since the pyrimidine derivatives in question are non-toxic inhibitors of prostaglandin E2 (PGE2) production, they can be considered suitable substances for developing new drugs for the treatment of induced diseases and their severity is potentiated by the overproduction of PGE2. This is particularly the case for the treatment of inflammatory and cancer diseases. They may also be used as anti-angiogenic, immunomodulatory, antiproliferative or anti-cancer drugs.

The patent-protected solution is the result of the cooperation of teams led by Ing. Zlatko Janeba, CSc. (IOCB CAS) and RNDr. Zdeněk Zídek, DrSc. (IEM CAS).

We congratulate both research teams and wish them many more scientific successes.